Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings results on Monday. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03, Bloomberg Earnings reports.

Kura Oncology (KURA) traded down 4.2841% during midday trading on Tuesday, hitting $9.9066. The stock had a trading volume of 43,218 shares. The company’s market cap is $194.83 million. Kura Oncology has a 12-month low of $3.89 and a 12-month high of $12.10. The company has a 50-day moving average price of $8.81 and a 200-day moving average price of $8.52.

KURA has been the topic of several recent analyst reports. Cann reiterated a “buy” rating and issued a $16.00 price target on shares of Kura Oncology in a research note on Monday, May 15th. Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a research note on Tuesday. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a research note on Wednesday, June 28th. Finally, Zacks Investment Research lowered shares of Kura Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $14.00.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/08/kura-oncology-inc-kura-issues-quarterly-earnings-results.html.

Several large investors have recently modified their holdings of KURA. State of Wisconsin Investment Board purchased a new stake in shares of Kura Oncology during the second quarter worth $102,000. Oppenheimer & Co. Inc. increased its stake in shares of Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after buying an additional 1,600 shares during the period. Segantii Capital Management Ltd purchased a new stake in shares of Kura Oncology during the first quarter worth $120,000. Rhumbline Advisers purchased a new stake in shares of Kura Oncology during the second quarter worth $131,000. Finally, Nationwide Fund Advisors purchased a new stake in shares of Kura Oncology during the first quarter worth $136,000. Institutional investors and hedge funds own 50.17% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Earnings History for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.